Why did Lupin (LUPIN) stock move recently?

On 7/22/2026, Lupin moved -4.3% — Lupin shares fell with other Indian pharma stocks after reports of fresh US tariffs proposed by Trump on generic medicine imports. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Lupin (LUPIN) overvalued or fairly valued?

MarketChacha shows Lupin's valuation in context — a forward P/E of about 20.6, a price-to-book of about 4.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Lupin's revenue?

Lupin reported revenue of ₹19,513 Cr for FY2026, with net profit of ₹6,367 Cr, per official filings.

What is the share price of Lupin (LUPIN)?

Lupin last traded at ₹2,110.00 (-2.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Lupin

LUPIN · NSE · Pharma · India

Snapshot

TickerLUPIN

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees26,021

HeadquartersMumbai, India

Websitewww.lupin.com

Filings tracked13

About Lupin

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Who owns it

Promoters47.0%
Institutions35.7%
Public & other17.3%

230 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend2.6% → 19.1%

Margin has expanded by about 16.5 points — the business is getting more profitable.

Growth qualityrev 14% · PAT 88%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹7,498 Cr · EPS 20.46

Est. earnings growth -36.4%

Next fiscal year

Rev ₹32,201 Cr · EPS 102.24

Est. earnings growth +6.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹27,958 Cr

Net margin

19.1%

Revenue CAGR (3y)

+18.9%

Profit CAGR (3y)

+131.5%

Net profit (FY2026)

₹5,333 Cr

Ask MarketChacha about LUPIN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 22, 2026
Lupin shares fell with other Indian pharma stocks after reports of fresh US tariffs proposed by Trump on generic medicine imports.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹27,958 Cr	₹5,333 Cr	19.1%
FY2025	₹22,708 Cr	₹3,282 Cr	14.5%
FY2024	₹20,011 Cr	₹1,914 Cr	9.6%
FY2023	₹16,642 Cr	₹430 Cr	2.6%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹8,277 Cr	₹1,415 Cr	17.1%
Q4 FY26	₹7,475 Cr	₹1,460 Cr	19.5%
Q3 FY26	₹7,168 Cr	₹1,176 Cr	16.4%
Q2 FY26	₹7,048 Cr	₹1,478 Cr	21.0%
Q1 FY26	₹6,258 Cr	₹1,219 Cr	19.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating
ESG Rating by Crisil ESG Ratings & Analytics Ltd.
BSE8/28/2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
ESG Rating by ESG Risk Assessment and Insights Limited.
BSE8/24/2026
Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.
VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.
BSE8/20/2026
Press Release / Media Release
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.
BSE8/17/2026
Press Release / Media Release
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
BSE8/10/2026
Investor Presentation
Investor Presentation (Revised) - Q1 FY27 Results
BSE8/7/2026
Investor Presentation
Investor Presentation- Q1 FY2027
BSE8/6/2026
Press Release / Media Release
Lupin Q1 FY2027 Results
BSE8/6/2026
Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
BSE8/6/2026
Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
BSE8/6/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer''s Report.
BSE8/4/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.
BSE8/4/2026material
Press Release / Media Release
Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.
BSE7/31/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.